Intraoperative management of a dysfibrinogenemic patients with gastric cancer.
The intraoperative management of a dysfibrinogenemic patient with gastric cancer is reported herein. In order to avoid abnormal bleeding, the fibrinogen level during a cancer-operation should be maintained above 60 mg/dl. Cryoprecipitate, however, is not suitable for fibrinogen supplementation because of its short life in vivo.
D000230:Adenocarcinoma / Q000150:complications / Q000601:surgery*; D000328:Adult; D000347:Afibrinogenemia / Q000150:complications / Q000188:drug therapy* / Q000235:genetics; D005169:Factor VIII / Q000627:therapeutic use; D005260:Female; D005340:Fibrinogen / Q000627:therapeutic use; D005353:Fibronectins / Q000627:therapeutic use; D005743:Gastrectomy; D006801:Humans; D007431:Intraoperative Complications / Q000188:drug therapy*; D008297:Male; D010375:Pedigree; D013274:Stomach Neoplasms / Q000150:complications / Q000601:surgery*
D005353:Fibronectins; C026912:cryoprecipitate coagulum; D005169:Factor VIII; D005340:Fibrinogen